Closing remarks and treatment guidelinesPICCART, M.European journal of cancer. Supplement (1990). 2001, Vol 37, Num 1, pp S30-S33, issn 1359-6349Article

Proposed treatment guidelines for HER2-positive metastatic breast cancer in EuropePICCART, M. J.Annals of oncology. 2001, Vol 12, pp 89-94, issn 0923-7534, SUP1Conference Paper

Routine follow-up of patients after primary therapy for early breast cancer: changing concepts and challenges for the futureTOMIAK, E; PICCART, M.Annals of oncology. 1993, Vol 4, Num 3, pp 199-204, issn 0923-7534Article

Le cancer épithélial de l'ovaire : challenge in cancérologie gynécologique = Epithelial ovarian cancer: challenge in gynecologic oncologyDAUPLAT, J; PICCART, M.Pathologie et biologie. 1991, Vol 39, Num 9, pp 823-824, issn 0369-8114Article

The contribution of molecular markers to the prediction of response in the treatment of breast cancer : A review of the literature on HER-2, p53 and BCL-2HAMILTON, A; PICCART, M.Annals of oncology. 2000, Vol 11, Num 6, pp 647-663, issn 0923-7534Article

Intraperitoneal chemotherapy: belly-bath or pain-in-the-side?HOCHSTER, H. S; PICCART, M.European journal of cancer & clinical oncology. 1987, Vol 23, Num 3, pp 259-261, issn 0277-5379Article

The AURORA initiative for metastatic breast cancerZARDAVAS, D; MAETENS, M; CAMPBELL, P et al.British journal of cancer. 2014, Vol 111, Num 10, pp 1881-1887, issn 0007-0920, 7 p.Article

Neoadjuvant treatments for triple-negative breast cancer (TNBC)VON MINCKWITZ, G; MARTIN, M.Annals of oncology. 2012, Vol 23, issn 0923-7534, vi35-vi39, SUP6Article

Validation of the Institut Curie simplified prognostic score for breast cancer meningeal carcinomatosisBIDARD, F.-C; LOSSIGNOL, D; LARSIMONT, D et al.Annals of oncology. 2011, Vol 22, Num 2, pp 480-482, issn 0923-7534, 3 p.Article

A significant proportion of elderly patients develop hormone-dependent luminal-B tumours associated with aggressive characteristics : Geriatric oncologyDURBECQ, V; AMEYE, L; LARSIMONT, D et al.Critical reviews in oncology/hematology. 2008, Vol 67, Num 1, pp 80-92, issn 1040-8428, 13 p.Article

The Hamburg statement: the partnership driving the European agenda on breast cancerJASSEM, J; BUCHANAN, M; JÄNICKE, F et al.European journal of cancer (1990). 2004, Vol 40, Num 12, pp 1810-1811, issn 0959-8049, 2 p.Article

EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx®, Doxil®) at a 6-week interval in patients with metastatic breast cancerHAMILTON, A; BIGANZOLI, L; BRUNING, P et al.Annals of oncology. 2002, Vol 13, Num 6, pp 910-918, issn 0923-7534Article

Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumoursAWADA, A; ESKENS, F. A. L. M; VERWEIJ, J et al.European journal of cancer (1990). 2002, Vol 38, Num 17, pp 2272-2278, issn 0959-8049, 7 p.Article

An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancerBONNEFOI, H; BIGANZOLI, L; CUFER, T et al.Breast cancer research and treatment. 2001, Vol 70, Num 1, pp 55-63, issn 0167-6806Article

Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancerVERWEIJ, J; WANDERS, J; NIELSEN, A. L et al.Annals of oncology. 1994, Vol 5, Num 4, pp 375-376, issn 0923-7534Article

Successful re-treatment with taxol after major hypersensitivity reactionsPEEREBOOM, D. M; DONEHOWER, R. C; EISENHAUER, E. A et al.Journal of clinical oncology. 1993, Vol 11, Num 5, pp 885-890, issn 0732-183XArticle

Ureteral obstruction in patients with breast cancerRECLOUX, P; WEISER, M; PICCART, M et al.Cancer. 1988, Vol 61, Num 9, pp 1904-1907, issn 0008-543X, 4 p.Article

Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancerPICCART, M; PARKER, L. M; PRITCHARD, K. I et al.Annals of oncology. 2003, Vol 14, Num 7, pp 1017-1025, issn 0923-7534, 9 p.Article

Stratégies thérapeutiques optimales dans le cancer épithélial de l'ovaire en 1997 = Optimal therapy for advanced epithelial ovarian cancer in 1997PICCART, M. J; NOGARET, J.-M.Revue médicale de Bruxelles. 1997, Vol 18, Num 4, pp 198-203, issn 0035-3639Conference Paper

Genomic grade adds prognostic value in invasive lobular carcinomatMETZGER-FILHO, O; MICHIELS, S; HUSSY, S et al.Annals of oncology. 2013, Vol 24, Num 2, pp 377-384, issn 0923-7534, 8 p.Article

A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993)COLEMAN, R. E; BIGANZOLI, L; CANNEY, P et al.European journal of cancer (1990). 2006, Vol 42, Num 7, pp 882-887, issn 0959-8049, 6 p.Article

Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer : An EORTC phase III study (10863)BEEX, L; ROSE, C; BAILA, L et al.European journal of cancer (1990). 2006, Vol 42, Num 18, pp 3178-3185, issn 0959-8049, 8 p.Article

Correlation between topoisomerase-IIα gene amplification and protein expression in HER-2 amplified breast cancerDURBECQ, V; DESMEDT, C; LARSIMONT, D et al.International journal of oncology. 2004, Vol 25, Num 5, pp 1473-1479, issn 1019-6439, 7 p.Article

The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'ATALAY, G; DIRIX, L; PICCART, M et al.Annals of oncology. 2004, Vol 15, Num 2, pp 211-217, issn 0923-7534, 7 p.Article

An EORTC phase I study of capecitabine (Xeloda®) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancerBONNEFOI, H; BIGANZOLI, L; MAURIAC, L et al.European journal of cancer (1990). 2003, Vol 39, Num 9, pp 1277-1283, issn 0959-8049, 7 p.Article